Results of esketamine administration in a Greek population; A case series.

Esketamine is a non-selective, competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor in the brain. Through NMDA receptor antagonism, esketamine causes a transient increase in glutamate release, leading to increases in neurotrophic signaling and restoration of synaptic function in brain regions involved in mood regulation and emotional behavior. Several randomized clinical trials have shown its effectiveness in reducing the symptoms of depression in some people, despite its short-term side effects that include mainly disorientation, dizziness, nausea, and increased blood pressure.

Rapid cycling in bipolar disorder: a systematic review.

Objective: THE long-term course of bipolar disorder is typified by recurring mood episodes of opposite polarity as well as mixed states. Rapid-cycling bipolar disorder refers to the presence of at least 4 mood episodes in the previous 12 months that meet the criteria for manic, hypomanic, or major depressive episode. The purpose of this study was to synthesize data regarding prevalence, clinical correlates, and familial/genetic aspects related to rapid cycling in bipolar disorder.